Singapore Markets closed
Straits Times Index
3,190.71 -34.64 (-1.07%) S&P 500
3,923.68 -165.17 (-4.04%) Dow
31,490.07 -1,164.52 (-3.57%) Nasdaq
11,418.15 -566.37 (-4.73%) BTC-USD
29,570.08 +45.50 (+0.15%) CMC Crypto 200
656.75 -13.92 (-2.08%)
Nuvation Bio Inc. (NUVB)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 4.2700 |
| Open | 4.1500 |
| Bid | 3.3300 x 1300 |
| Ask | 5.8500 x 1200 |
| Day's range | 4.0200 - 4.2000 |
| 52-week range | 3.5850 - 15.2300 |
| Volume | |
| Avg. volume | 913,629 |
| Market cap | 886.091M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Nuvation Bio Reports First Quarter 2022 Financial Results and Provides Business Update
NEW YORK, May 09, 2022--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported its financial results for the first quarter ended March 31, 2022, and provided a business update.
- Business Wire
Nuvation Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
NEW YORK, February 28, 2022--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported financial results for the fourth quarter and full year ended December 31, 2021, and provided a business update.
© 2022 Yahoo. All rights reserved.
